| MeSH term | MeSH ID | Detail |
|---|---|---|
| Osteoporotic Fractures | D058866 | 1 associated lipids |
| Cleidocranial Dysplasia | D002973 | 1 associated lipids |
| Prediabetic State | D011236 | 1 associated lipids |
| Carcinoma, Neuroendocrine | D018278 | 2 associated lipids |
| Osteophyte | D054850 | 2 associated lipids |
| Prenatal Exposure Delayed Effects | D011297 | 2 associated lipids |
| Pericardial Effusion | D010490 | 2 associated lipids |
| Lymphocytosis | D008218 | 2 associated lipids |
| Radicular Cyst | D011842 | 2 associated lipids |
| Gingival Recession | D005889 | 2 associated lipids |
7-octadecynoic acid
7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.
Cross Reference
There are no associated biomedical information in the current reference collection.
Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.
Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.
Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid
All references with 7-octadecynoic acid
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Xing L et al. | Osteoclast precursors, RANKL/RANK, and immunology. | 2005 | Immunol. Rev. | pmid:16313338 |
| Tanaka S et al. | Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system. | 2005 | Immunol. Rev. | pmid:16313339 |
| Horowitz MC et al. | B cells and osteoblast and osteoclast development. | 2005 | Immunol. Rev. | pmid:16313346 |
| Clowes JA et al. | The role of the immune system in the pathophysiology of osteoporosis. | 2005 | Immunol. Rev. | pmid:16313351 |
| Walsh NC et al. | Rheumatic diseases: the effects of inflammation on bone. | 2005 | Immunol. Rev. | pmid:16313352 |
| Kraj M et al. | Correlation of osteoprotegerin and sRANKL concentrations in serum and bone marrow of multiple myeloma patients. | 2005 Sep-Oct | Arch. Immunol. Ther. Exp. (Warsz.) | pmid:16314829 |
| Jiang J et al. | LTB4 can directly stimulate human osteoclast formation from PBMC independent of RANKL. | 2005 | Artif Cells Blood Substit Immobil Biotechnol | pmid:16317958 |
| Galluzzi F et al. | Osteoprotegerin serum levels in children with type 1 diabetes: a potential modulating role in bone status. | 2005 | Eur. J. Endocrinol. | pmid:16322394 |
| Raisz LG | Pathogenesis of osteoporosis: concepts, conflicts, and prospects. | 2005 | J. Clin. Invest. | pmid:16322775 |
| Schoppet M et al. | Osteoprotegerin (OPG) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) levels in atherosclerosis. | 2006 | Atherosclerosis | pmid:16325821 |
| Kieslinger M et al. | EBF2 regulates osteoblast-dependent differentiation of osteoclasts. | 2005 | Dev. Cell | pmid:16326388 |
| Boyce BF et al. | Osteoprotegerin, the bone protector, is a surprising target for beta-catenin signaling. | 2005 | Cell Metab. | pmid:16330319 |
| Mandelin J et al. | Human osteoblasts produce cathepsin K. | 2006 | Bone | pmid:16337236 |
| Yamazaki H and Sasaki T | Effects of osteoprotegerin administration on osteoclast differentiation and trabecular bone structure in osteoprotegerin-deficient mice. | 2005 | J Electron Microsc (Tokyo) | pmid:16339792 |
| Vidal C et al. | TNFRSF11B gene variants and bone mineral density in postmenopausal women in Malta. | 2006 | Maturitas | pmid:16343827 |
| Wutzl A et al. | Bone morphogenetic proteins 5 and 6 stimulate osteoclast generation. | 2006 | J Biomed Mater Res A | pmid:16355411 |
| Wang YD et al. | [Predominant effect of bushen ningxin decoction on postmenopausal osteoporosis in mice]. | 2005 | Zhongguo Zhong Xi Yi Jie He Za Zhi | pmid:16355616 |
| Wada T et al. | RANKL-RANK signaling in osteoclastogenesis and bone disease. | 2006 | Trends Mol Med | pmid:16356770 |
| Ishii R et al. | High serum values of soluble CD154, IL-2 receptor, RANKL and osteoprotegerin in Langerhans cell histiocytosis. | 2006 | Pediatr Blood Cancer | pmid:16358318 |
| Kim SW et al. | Effects of mushroom, Pleurotus eryngii, extracts on bone metabolism. | 2006 | Clin Nutr | pmid:16359759 |
| Padagas J et al. | The receptor activator of nuclear factor-kappaB ligand inhibitor osteoprotegerin is a bone-protective agent in a rat model of chronic renal insufficiency and hyperparathyroidism. | 2006 | Calcif. Tissue Int. | pmid:16362459 |
| Bi Y et al. | Biglycan deficiency increases osteoclast differentiation and activity due to defective osteoblasts. | 2006 | Bone | pmid:16364709 |
| Han X et al. | Bacterial-responsive B lymphocytes induce periodontal bone resorption. | 2006 | J. Immunol. | pmid:16365458 |
| Iguchi H et al. | Effects of anti-parathyroid hormone-related protein monoclonal antibody and osteoprotegerin on PTHrP-producing tumor-induced cachexia in nude mice. | 2006 | J. Bone Miner. Metab. | pmid:16369893 |
| Hermann-Arnhof KM et al. | Initially elevated osteoprotegerin serum levels may predict a perioperative myocardial lesion in patients undergoing coronary artery bypass grafting. | 2006 | Crit. Care Med. | pmid:16374159 |
| Rasmussen LM et al. | Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients. | 2006 | Eur. J. Endocrinol. | pmid:16381994 |
| Catrina AI et al. | Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis. | 2006 | Arthritis Rheum. | pmid:16385498 |
| Garlet GP et al. | Cytokine pattern determines the progression of experimental periodontal disease induced by Actinobacillus actinomycetemcomitans through the modulation of MMPs, RANKL, and their physiological inhibitors. | 2006 | Oral Microbiol. Immunol. | pmid:16390336 |
| Van Poznak C et al. | Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours. | 2006 | J. Clin. Pathol. | pmid:16394281 |
| Hsu HC et al. | Tumor necrosis factor ligand-receptor superfamily and arthritis. | 2006 | Curr. Dir. Autoimmun. | pmid:16394654 |
| Nakamura M et al. | [Bone remodeling and mineral homeostasis]. | 2006 | Clin Calcium | pmid:16397350 |
| Toruner M et al. | Antianoikis effect of nuclear factor-kappaB through up-regulated expression of osteoprotegerin, BCL-2, and IAP-1. | 2006 | J. Biol. Chem. | pmid:16407217 |
| Blair JM et al. | Mechanisms of disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis. | 2006 | Nat Clin Pract Oncol | pmid:16407878 |
| Gustafsson BI et al. | Serotonin and fluoxetine modulate bone cell function in vitro. | 2006 | J. Cell. Biochem. | pmid:16408289 |
| Kozaki K | [Current concepts of vascular calcification]. | 2005 | Nihon Ronen Igakkai Zasshi | pmid:16408509 |
| Lossdörfer S et al. | Maturation-state dependent response of human periodontal ligament cells to an intermittent parathyroid hormone exposure in vitro. | 2006 | J. Periodont. Res. | pmid:16409257 |
| Al-Fakhri N et al. | Expression of bone-regulating factors osteoprotegerin (OPG) and receptor activator of NF-kappaB ligand (RANKL) in heterotopic vascular ossification. | 2005 | Thromb. Haemost. | pmid:16411417 |
| Sandra F et al. | Osteoprotegerin (OPG) binds with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL): suppression of TRAIL-induced apoptosis in ameloblastomas. | 2006 | Oral Oncol. | pmid:16413220 |
| Evans BA et al. | Human osteoblast precursors produce extracellular adenosine, which modulates their secretion of IL-6 and osteoprotegerin. | 2006 | J. Bone Miner. Res. | pmid:16418778 |
| Berry JE et al. | JunB as a downstream mediator of PTHrP actions in cementoblasts. | 2006 | J. Bone Miner. Res. | pmid:16418780 |
| Fan X et al. | Response to mechanical strain in an immortalized pre-osteoblast cell is dependent on ERK1/2. | 2006 | J. Cell. Physiol. | pmid:16419041 |
| Zhang B et al. | [Molecular mechanism of bone absorption in osteoclast]. | 2005 | Sheng Wu Yi Xue Gong Cheng Xue Za Zhi | pmid:16422121 |
| Sandberg WJ et al. | Enhanced T-cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization. | 2006 | Arterioscler. Thromb. Vasc. Biol. | pmid:16424351 |
| Takasu H et al. | c-Fos protein as a target of anti-osteoclastogenic action of vitamin D, and synthesis of new analogs. | 2006 | J. Clin. Invest. | pmid:16424941 |
| Neumann T et al. | Osteoprotegerin reduces the loss of periarticular bone mass in primary and secondary spongiosa but does not influence inflammation in rat antigen-induced arthritis. | 2006 | Inflamm. Res. | pmid:16429254 |
| Dobnig H et al. | Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients. | 2006 | Osteoporos Int | pmid:16435076 |
| Kananen K et al. | Serum osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) concentrations in allogeneic stem cell transplant-recipients: a role in bone loss? | 2006 | Osteoporos Int | pmid:16437190 |
| Rosso DA et al. | Elevated serum levels of the decoy receptor osteoprotegerin in children with Langerhans cell histiocytosis. | 2006 | Pediatr. Res. | pmid:16439593 |
| Dewar AL et al. | Imatinib as a potential antiresorptive therapy for bone disease. | 2006 | Blood | pmid:16449525 |
| Granchi D et al. | Plasma levels of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in patients with neuroblastoma. | 2006 | Int. J. Cancer | pmid:16450378 |
| Liu D et al. | Effect of interleukin-10 on gene expression of osteoclastogenic regulatory molecules in the rat dental follicle. | 2006 | Eur. J. Oral Sci. | pmid:16460340 |
| Cohen S | Role of RANK ligand in normal and pathologic bone remodeling and the therapeutic potential of novel inhibitory molecules in musculoskeletal diseases. | 2006 | Arthritis Rheum. | pmid:16463406 |
| Holen I and Shipman CM | Role of osteoprotegerin (OPG) in cancer. | 2006 | Clin. Sci. | pmid:16464170 |
| Kobayashi Y and Takahashi N | [The pathophysiology of osteoporosis/osteopenia in gene mutant mice]. | 2006 | Clin Calcium | pmid:16465035 |
| Zehnder AF et al. | Osteoprotegrin knockout mice demonstrate abnormal remodeling of the otic capsule and progressive hearing loss. | 2006 | Laryngoscope | pmid:16467704 |
| Yildirim S et al. | Human cytomegalovirus, Epstein-Barr virus and bone resorption-inducing cytokines in periapical lesions of deciduous teeth. | 2006 | Oral Microbiol. Immunol. | pmid:16476020 |
| Yamamoto T et al. | Mechanical stress induces expression of cytokines in human periodontal ligament cells. | 2006 | Oral Dis | pmid:16476039 |
| GarcÃa-Valdecasas-Campelo E et al. | Serum osteoprotegerin and RANKL levels in chronic alcoholic liver disease. | 2006 May-Jun | Alcohol Alcohol. | pmid:16476762 |
| Lamghari M et al. | Leptin effect on RANKL and OPG expression in MC3T3-E1 osteoblasts. | 2006 | J. Cell. Biochem. | pmid:16479591 |
| Wang Q et al. | [The molecule mechanism of soybean isoflavaones antagonizing bone loss induced by postmenopausal osteoporosis]. | 2005 | Zhong Yao Cai | pmid:16479929 |
| Sun SG et al. | Bone stromal cells in pagetic bone and Paget's sarcoma express RANKL and support human osteoclast formation. | 2006 | J. Pathol. | pmid:16482498 |
| Guang-Da X et al. | Alteration of plasma concentrations of OPG before and after levothyroxine replacement therapy in hypothyroid patients. | 2005 | J. Endocrinol. Invest. | pmid:16483173 |
| Olmos JM et al. | Factors other than glucocorticoids are involved in the osteoblast activity decrease caused by tissue injury. | 2006 | Clin. Endocrinol. (Oxf) | pmid:16487437 |
| Roux S | RANKL inhibitors: a bright future? | 2006 | Joint Bone Spine | pmid:16488648 |
| Cross SS et al. | Expression of receptor activator of nuclear factor kappabeta ligand (RANKL) and tumour necrosis factor related, apoptosis inducing ligand (TRAIL) in breast cancer, and their relations with osteoprotegerin, oestrogen receptor, and clinicopathological variables. | 2006 | J. Clin. Pathol. | pmid:16489180 |
| Albalate M et al. | Association between phosphate removal and markers of bone turnover in haemodialysis patients. | 2006 | Nephrol. Dial. Transplant. | pmid:16490746 |
| Pettit AR et al. | RANKL protein is expressed at the pannus-bone interface at sites of articular bone erosion in rheumatoid arthritis. | 2006 | Rheumatology (Oxford) | pmid:16490750 |
| Middleton-Hardie C et al. | Deletion of aspartate 182 in OPG causes juvenile Paget's disease by impairing both protein secretion and binding to RANKL. | 2006 | J. Bone Miner. Res. | pmid:16491292 |
| Mazziotti G et al. | Increased serum osteoprotegerin values in long-lived subjects: different effects of inflammation and bone metabolism. | 2006 | Eur. J. Endocrinol. | pmid:16498049 |
| Iwasaki Y et al. | Uremic toxin and bone metabolism. | 2006 | J. Bone Miner. Metab. | pmid:16502128 |
| Jono S et al. | Vascular calcification in chronic kidney disease. | 2006 | J. Bone Miner. Metab. | pmid:16502129 |
| Nishi H et al. | No change in circulating osteoprotegerin levels by intravenous calcitriol therapy among dialysis patients with secondary hyperparathyroidism. | 2006 | Clin. Nephrol. | pmid:16509469 |
| Wohlfahrt JC et al. | No association between selected candidate gene polymorphisms and severe chronic periodontitis. | 2006 | J. Periodontol. | pmid:16512757 |
| Magal I et al. | Serum levels of osteoprotegerin and osteoprotegerin polymorphisms in Gaucher disease. | 2006 | Br. J. Haematol. | pmid:16512834 |
| Mehrotra M et al. | Fluid flow induces Rankl expression in primary murine calvarial osteoblasts. | 2006 | J. Cell. Biochem. | pmid:16514640 |
| Evans CE et al. | Age of donor alters the effect of cyclic hydrostatic pressure on production by human macrophages and osteoblasts of sRANKL, OPG and RANK. | 2006 | BMC Musculoskelet Disord | pmid:16519799 |
| McClung MR | Inhibition of RANKL as a treatment for osteoporosis: preclinical and early clinical studies. | 2006 | Curr Osteoporos Rep | pmid:16527005 |
| Wittersheim E et al. | OPG, RANK-L, bone metabolism, and BMD in patients on peritoneal dialysis and hemodialysis. | 2006 | Clin. Biochem. | pmid:16530745 |
| Lee L et al. | A role for the immunomodulatory molecules CD200 and CD200R in regulating bone formation. | 2006 | Immunol. Lett. | pmid:16530849 |
| Nadiminty N et al. | Prostate-specific antigen modulates genes involved in bone remodeling and induces osteoblast differentiation of human osteosarcoma cell line SaOS-2. | 2006 | Clin. Cancer Res. | pmid:16533764 |
| Fukumoto S et al. | Current topics in pharmacological research on bone metabolism: osteoclast differentiation regulated by glycosphingolipids. | 2006 | J. Pharmacol. Sci. | pmid:16538029 |
| Hesry V et al. | Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players. | 2006 | Prostate | pmid:16541419 |
| Dovio A et al. | Circulating osteoprotegerin and soluble RANKL: do they have a future in clinical practice? | 2005 | J. Endocrinol. Invest. | pmid:16550717 |
| Walsh MC et al. | Osteoimmunology: interplay between the immune system and bone metabolism. | 2006 | Annu. Rev. Immunol. | pmid:16551243 |
| Kanzaki S et al. | Resorption of auditory ossicles and hearing loss in mice lacking osteoprotegerin. | 2006 | Bone | pmid:16564235 |
| Maddi A et al. | Long wave ultrasound may enhance bone regeneration by altering OPG/RANKL ratio in human osteoblast-like cells. | 2006 | Bone | pmid:16567138 |
| Kim HR et al. | Elevated serum levels of soluble receptor activator of nuclear factors-kappaB ligand (sRANKL) and reduced bone mineral density in patients with ankylosing spondylitis (AS). | 2006 | Rheumatology (Oxford) | pmid:16567356 |
| Aihara N et al. | Low-energy irradiation stimulates formation of osteoclast-like cells via RANK expression in vitro. | 2006 | Lasers Med Sci | pmid:16568210 |
| Liu Y et al. | [Effect of Herba Epimedii Flavone on expression of OPG and RANKL in rat osteoblasts]. | 2005 | Zhong Yao Cai | pmid:16568663 |
| Wang L et al. | Integrin beta1 silencing in osteoblasts alters substrate-dependent responses to 1,25-dihydroxy vitamin D3. | 2006 | Biomaterials | pmid:16569430 |
| Miller CS et al. | Salivary biomarkers of existing periodontal disease: a cross-sectional study. | 2006 | J Am Dent Assoc | pmid:16570465 |
| Hofbauer LC et al. | Tumour necrosis factor-related apoptosis-inducing ligand and osteoprotegerin serum levels in psoriatic arthritis. | 2006 | Rheumatology (Oxford) | pmid:16574701 |
| Balga R et al. | Tumor necrosis factor-alpha: alternative role as an inhibitor of osteoclast formation in vitro. | 2006 | Bone | pmid:16580896 |
| Abe M | [Bone disease in multiple myeloma and its mechanism]. | 2006 | Clin Calcium | pmid:16582506 |
| Endo I and Inoue D | [Treatment of malignancy-associated hypercalcemia]. | 2006 | Clin Calcium | pmid:16582519 |
| Malik MH et al. | Genetic susceptibility to hip arthroplasty failure--association with the RANK/OPG pathway. | 2006 | Int Orthop | pmid:16583245 |
| Graziani F et al. | The in vitro effect of different PRP concentrations on osteoblasts and fibroblasts. | 2006 | Clin Oral Implants Res | pmid:16584418 |
| Fisher JL et al. | Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically. | 2006 | Cancer Res. | pmid:16585187 |
| Mori K et al. | Modulation of mouse RANKL gene expression by Runx2 and PKA pathway. | 2006 | J. Cell. Biochem. | pmid:16598781 |
| Hofbauer LC et al. | Interleukin-4 differentially regulates osteoprotegerin expression and induces calcification in vascular smooth muscle cells. | 2006 | Thromb. Haemost. | pmid:16601843 |